Clinical Trial Detail

NCT ID NCT02872025
Title Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Laura Esserman
Indications

ductal carcinoma in situ

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.